BRIEF: Qyuns Therapeutics secures CSRC approval for full H-share circulation
Biopharmaceutical company Qyuns Therapeutics Co. Ltd. (2509.HK) announced on Tuesday that the China Securities Regulatory Commission (CSRC) has approved its plan to convert 17.32 million of its domestic shares into…
Sunho Biologics gets green light for downsized IPO
The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…